Delivery Order SPE2DB20D2014-SPE2DB25FB72F
- Not listed
- The Defense Logistics Agency awarded a $11,741.33 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injectors on June 18, 2025, with an ultimate completion date of June 20, 2025. This non-competitive, firm fixed-price delivery order was issued under a child contract structure, leveraging AmerisourceBergen's established relationship with the federal government's medical supply chain. The contract was performed at the company's corporate office location in...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $24,505.16 by the Defense Logistics Agency (DLA) on September 5, 2025, for the supply of Enbrel 50 mg/mL SureClick auto-injectors. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 8, 2025. The contract represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply agreement...
- AmerisourceBergen Drug Corp was awarded a $4,626.77 firm fixed-price delivery order by the Defense Logistics Agency (DLA) on August 21, 2025, for the supply of Enbrel 50 mg/mL SureClick auto-injectors. The contract is non-set-aside and competitively awarded, with an ultimate completion date of August 22, 2025. Performance will be executed from the company's Conshohocken, Pennsylvania location, which serves as its corporate headquarters. This delivery order is issued under AmerisourceBergen's...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency valued at $74,662.13 for the supply of Enbrel 50 mg/ml SureClick auto-injectors. The contract, awarded on September 11, 2025, with an ultimate completion date of September 12, 2025, is structured as a firm fixed price delivery order with no set-aside designation. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate office....
- The Defense Logistics Agency awarded a $25,765.04 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of ENBREL 50 MG/ML SureClick auto-injectors. The contract, which represents a child order under a larger procurement vehicle, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 4, 2025. This delivery order was competitively awarded with no set-aside designation,...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $39,637.01 for Enbrel 50 mg/mL SureClick auto-injectors on June 16, 2025, with an ultimate completion date of June 17, 2025. This firm fixed-price, non-competitive delivery order is funded through the Defense Logistics Agency's Medical Supply Chain and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $39,049.72 delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Enbrel 50 mg/mL SureClick auto-injectors. This competitively awarded, firm fixed-price contract serves as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical will be delivered to AmerisourceBergen's corporate office...
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) valued at $9,253.56 for the supply of Enbrel 50 mg/mL SureClick auto-injectors. This firm fixed price, competitively awarded contract carries an ultimate completion date of August 11, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under a larger indefinite delivery contract vehicle and reflects the DLA's...
- The Defense Logistics Agency awarded a delivery order valued at $5,827.97 to AmerisourceBergen Drug Corp for the supply of ENBREL 50 mg/ml SureClick auto-injectors. This firm fixed-price delivery order, issued on August 6, 2025, with an ultimate completion date of August 7, 2025, represents a non-competitive delivery against AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a $62,114.93 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/mL SureClick auto-injectors, with an ultimate completion date of May 20, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The product will be performed at the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FB72FDelivery Order
AmerisourceBergen Drug Corp was awarded a delivery order valued at $4,626.77 by the Defense Logistics Agency on April 23, 2025, for the supply of ENBREL 50 mg/mL SureClick auto-injectors. This is a firm fixed-price, non-set-aside contract with a completion date of April 24, 2025, and represents a child order under AmerisourceBergen's larger prime indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its pharmaceutical distribution operations. This delivery order falls under AmerisourceBergen's comprehensive $999.999 billion indefinite delivery contract with DLA Troop Support Medical (SPE2DX) that extends through December 2026, which serves as the global pharmaceutical prime vendor vehicle supporting military healthcare programs. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen supplies a broad portfolio of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. ENBREL is a biologic therapeutic indicated for rheumatoid arthritis and other autoimmune conditions, demonstrating the company's role in delivering specialized pharmaceutical products to support federal military and veteran healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.6k | 4/23/25 |